◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksR › RADX

Radiopharm Theranostics Limited (RADX) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-09-08

Radiopharm Theranostics Limited (RADX) operates in the Biotechnology industry and is headquartered in Carlton, Australia. Its market capitalization is roughly $30 million. In the fiscal year ended 2025-06-30, RADX reported AUD 4M in revenue and (AUD 38M) in net income.

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.

Interactive charts & full statements → Open the RADX valuation workbench →

RADX Revenue & Earnings History — Annual Income Statement

Income statement2025-06-302024-06-302023-06-302022-06-30
Total RevenueAUD 4MAUD 0MAUD 0MAUD 0M
Gross ProfitAUD 0MAUD 0MAUD 0MAUD 0M
Operating Income (EBIT)(AUD 35M)(AUD 37M)(AUD 32M)(AUD 20M)
Net Income(AUD 38M)(AUD 48M)(AUD 35M)(AUD 30M)

AUD; AUDM / AUDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RADX Free Cash Flow History

RADX Balance Sheet History

Balance sheet2025-06-302024-06-302023-06-302022-06-30
Total AssetsAUD 86MAUD 72MAUD 75MAUD 83M
Total LiabilitiesAUD 44MAUD 45MAUD 29MAUD 20M

AUD; AUDM / AUDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RADX viewer.

Other Companies in Biotechnology

← RADIOCITYAll “R” companiesRAFE →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.